  Abbreviations, acronyms & symbols                                                           
  ----------------------------------- ------------------------------------------- --- ------- ----------------------------------------------------------
  CABG                                = Coronary artery bypass grafting               MACE    = Major adverse cardiac events
  CAD                                 = Coronary artery disease                       MI      = Myocardial infarction
  CI                                  = Confidence interval                           MOOSE   = Meta-analysis of Observational Studies in Epidemiology
  CNKI                                = China National Knowledge Infrastructure       MT      = Medical treatment
  CTO                                 = Chronic total occlusion                       OR      = *Odds ratio*
  CTO-SS                              = Chronic total occlusion SYNTAX score          PCI     = Percutaneous coronary intervention
  EMBASE                              = Excerpta Medica database                      RCT     = Randomized clinical trial
  HF                                  = Heart failure                                 UK      = United Kingdom

INTRODUCTION
============

Chronic total occlusion (CTO) has been reported to be in approximately 30% of patients with coronary heart disease^\[[@r1],[@r2]\]^. Currently, the management of CTO remains a challenge. Three strategies of management of CTO, including coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and medical treatment (MT), have been usually utilized, but which strategy is the best choice remains controversial. Ladwiniec et al.^\[[@r1]\]^ reported that PCI is associated with improved long-term survival compared with MT alone. Tomasello et al.^\[[@r2]\]^ also reported that PCI significantly improves the survival occurrence in comparison with MT and/or CABG. However, Fujino et al.^\[[@r3]\]^ found out that PCI does not reduce the risk of death or major adverse cardiac events (MACEs), when added to MT. Yang et al.^\[[@r4]\]^ also suggested that PCI did not reduce cardiac death compared with MT in the treatment of CTO. These observational studies and retrospective cohort studies have yielded conflicting results and no large multicenter randomized clinical trial (RCT) has ever tested whether PCI or CABG is superior to MT.

A recent meta-analysis comparing successful *vs*. failed PCI for CTO suggested that successful PCI recanalization of a CTO was associated with improved long-term clinical outcome compared with a failed intervention^\[[@r5]\]^. However, all the participants involved in this meta-analysis have received a CTO-PCI attempt. It is unclear how would be the prognosis of the CTO patients without a CTO-PCI attempt and receiving different management strategy. Therefore, the purpose of this study was to determine if PCI/CABG is associated with improved clinical outcomes compared with the outcomes of MT alone by performing a systematic review and meta-analysis of published studies.

METHODS
=======

We identified studies published in the China National Knowledge Infrastructure (CNKI) database, PubMed, Excerpta Medica database (EMBASE), Google Scholar, Cochrane Library, Web of Science, and \"Clinical trials\" registration websites from 1999 to October 2018 using the following keywords: \"chronic total occlusions\" (CTO); \"percutaneous coronary intervention\" (PCI); \"medical treatment\" (MT); \"coronary artery bypass graft\" (CABG); \"coronary artery disease\", and \"coronary heart disease\". The search strategy was as follows: \"chronic total occlusions\" OR \"CTO\" AND \"percutaneous coronary intervention\" OR \"PCI\" AND \"medical treatment\" OR \"MT\" AND \"coronary artery bypass graft\" OR \"CABG\" AND \"coronary heart disease\" OR \"CHD\" OR \"coronary artery disease\" OR \"CAD\".

Main outcome measures were all-cause mortality, cardiac death, MACEs, and myocardial infarction (MI). In the present study, we limited the search criteria to include studies published in the Chinese or English language. Additionally, we also identified studies by searching Clinicaltrials.gov and by hand-searching references cited in relevant publications as described previously^\[[@r6]\]^.

Data Sources and Study Search Strategy
--------------------------------------

In the present study, we included observational studies and cohort studies which: 1) enrolled patients with coronary CTO who received treatments of PCI, MT, or CABG; 2) compared the outcomes among treatments of MT, PCI, and CABG; and 3) reported all-cause mortality, MI, cardiac death, and MACE rates.

We excluded: 1) studies assessing the role of different treatment strategies in quality of life; 2) studies comparing outcomes of successful PCI *vs*. failure PCI for CTO unless the outcomes of MT or CABG were also reported; 3) studies that only focused on only one treatment strategy; and 4) studies not involving humans.

Study Selection
---------------

As shown in [Figure 1](#f1){ref-type="fig"}, our initial search yielded 727 citations. Of these, 702 (96.6%) were excluded by title and abstract search because of irrelevant content, non-English and non-Chinese articles, animal subjects, outcomes of interest not reported, or other reasons. The remaining 25 studies were full-text reviewed, and five studies were excluded due to the fact of being case reports or reviews. Furthermore, 12 studies were excluded due to the absence of the interest outcomes reported. Finally, 10 studies^\[[@r1]-[@r4],[@r7]-[@r12]\]^ met the inclusion criteria, and two studies were further excluded due to duplicated data^\[[@r12]\]^ and no exact data to be used^\[[@r7]\]^.

Fig. 1Flow diagram of the literature search and study selection.CABG=coronary artery bypass grafting; MT=medical treatment; PCI=percutaneous coronary intervention

Data Extraction
---------------

Data were extracted by two investigators (X.X and Y.Y.Z), using standardized data extraction forms. Discrepancies were resolved by consensus. The following contents were collected: name of the first author, year of publication, ethnicity or geographic location of the study subjects, study design, procedural, management strategy, ages, gender, and relevant outcomes.

Outcomes
--------

The primary outcomes for this systematic review were all-cause mortality and MACE. Secondary outcomes were MI and cardiac death.

Methodological Quality
----------------------

We performed this meta-analysis including study selection, data collection, and analysis, and reporting of the results according to the recommendations of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group^\[[@r13]\]^.

We calculated weighted *odds ratios* (ORs) and 95% confidence intervals (CIs) for categorical variables. Heterogeneity test was performed using Cochrane Q-statistic and I^2^-statistic^\[[@r14]\]^. Pooled effect sizes were determined using a fixed-effects model (the Mantel-Haenszel method) when heterogeneity was negligible (I^2^ \< 50%) or a random-effects model (the DerSimonian and Kacker method) when significant heterogeneity was present (I^2^ ≥ 50%). We also performed a sensitivity analysis to evaluate the effect of each study on the combined ORs by omitting each study in turn. Publication bias was visually estimated by assessing funnel plots and the Begg\'s test. All analyses were performed using RevMan 5.3 software (Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen) as described previously^\[[@r15],[@r16]\]^.

RESULTS
=======

Studies\' and Patients\' Characteristics
----------------------------------------

The characteristics of the eight studies that met eligibility criteria are displayed in [Table 1](#t1){ref-type="table"}. Of these, one is a prospective cohort study, one is an observational study, and six are retrospective cohort studies. The present analysis includes 6985 patients, of whom 2958 received MT, 3157 received PCI, and 613 received CABG. The mean age of the study participants was 64.4 years. The mean follow-up time was 4.3 years. The overall internal validity was moderate and is illustrated in [Table 2](#t2){ref-type="table"}.

###### 

Summary of key demographic characteristics of studies included in the meta-analysis.

  First author                  Publication year   Region              Sample size, n   Management strategy   Follow-up     Age, years                                   Male sex, %                     Outcomes
  ----------------------------- ------------------ ------------------- ---------------- --------------------- ------------- -------------------------------------------- ------------------------------- --------------------------------------------------------------------
  Fujino et al.^\[[@r3]\]^      2013               Netherlands         820              PCI, MT               7.2 years     \-                                           \-                              All-cause death, MACEs
  Gai et al.^\[[@r8]\]^         2015               China               253              PCI, MT, CABG         5 years       \-                                           \-                              All-cause death, MACEs, MI, stroke, HF
  Ladwiniec et al.^\[[@r1]\]^   2015               UK                  1957             PCI, MT, CABG         5 years       CABG:66.0±9.3 PCI: 63.2±10.1 MT: 65.8±10.7   CABG: 82.9 PCI: 73.1 MT: 77.7   All-cause death, MI, cardiac death, repeat revascularization
  Tomasello et al.^\[[@r2]\]^   2015               Italy               1777             PCI, MT, CABG         12 months     68.6±11.5                                    84.1                            MACE, MI, cardiac death
  Wiggers et al.^\[[@r9]\]^     1997               Denmark             154              CABG, MT              5 years       \-                                           \-                              All-cause death, MI
  Jang et al.^\[[@r10]\]^       2015               Republic of Korea   738              CABG, MT, PCI         3.5 years     MT: 65.6 ±12.0 CABG/PCI: 61.6±10.2           MT: 80.5 CABG/PCI: 83.5         All-cause death, MACE, MI, cardiac death, repeat revascularization
  Kim et al.^\[[@r11]\]^        2015               Republic of Korea   393              CABG, MT, PCI         46.5 months   CABG: 61.1±9.6 PCI: 62.0±11.1 MT:67.6±12.6   CABG: 87.0 PCI: 86.9 MT: 79.8   All-cause death, MACE, MI, cardiac death, repeat revascularization
  Yang et al.^\[[@r4]\]^        2016               Republic of Korea   1547             MT, PCI               45.8 months   PCI: 65.9±11.3 MT: 61.5±10.8                 PCI: 76.7 MT: 80.7              All-cause death, MACE, MI, cardiac death, repeat revascularization

CABG=coronary artery bypass grafting; HF=heart failure; MACE=major adverse cardiac event; MI=myocardial infarction; MT=medical treatment; PCI=percutaneous coronary intervention; UK=United Kingdom

###### 

Analysis of risk of bias.

  First author                  Publication year   Selection bias   Performance bias   Attrition bias   Detection bias   Multivariate adjustment for possible confounders
  ----------------------------- ------------------ ---------------- ------------------ ---------------- ---------------- --------------------------------------------------
  Fujino et al.^\[[@r3]\]^      2013               A                B                  A                A                Probably adequate
  Gai et al.^\[[@r8]\]^         2015               B                B                  A                A                Probably adequate
  Ladwiniec et al.^\[[@r1]\]^   2015               A                B                  A                A                Probably adequate
  Tomasello et al.^\[[@r2]\]^   2015               A                B                  B                A                Probably adequate
  Wiggers et al.^\[[@r9]\]^     1997               B                C                  B                B                Probably adequate
  Jang et al.^\[[@r10]\]^       2015               A                B                  B                B                Probably adequate
  Kim et al.^\[[@r11]\]^        2015               A                C                  C                C                Probably adequate
  Yang et al.^\[[@r4]\]^        2016               A                B                  C                D                Probably adequate

This analysis was performed by two independent reviewers. The overall bias of the combined studies was considered low.

A=risk of bias is low; B=risk of bias is moderate; C=risk of bias is high; D=unclear to determine

All-Cause Mortality
-------------------

Of the 6985 patients included in this meta-analysis, 836 (12%) died during follow-up. Comparing with MT, PCI presented decreased all-cause mortality (OR: 0.46, 95% CI: 0.36-0.60; *P*\<0.001) ([Figure 2A](#f2){ref-type="fig"}). Similarly, comparing with MT, CABG presented lower all-cause mortality (OR: 0.50, 95% CI: 0.36-0.69; *P*\<0.001) ([Figure 2B](#f2){ref-type="fig"}). And we did not find a significant difference between PCI and CABG groups in mortality rates ([Figure 2C](#f2){ref-type="fig"}).

Fig. 2Management strategy and all-cause mortality of chronic total occlusion patients.A=PCI vs. MT; B=CABG vs. MT; C=PCI vs. CABG. CABG=coronary artery bypass grafting; CI=confidence interval; MT=medical treatment; PCI=percutaneous coronary intervention

MACE
----

Six of eight studies reported 882 MACEs during follow-up. Comparing with MT, PCI presented lower incidence of MACE (OR: 0.55, 95% CI: 0.43-0.71; *P*\<0.001). A reduction in MACE incidence was observed not only in the PCI group, but also in the CABG group (OR: 0.50, 95% CI: 0.26-0.96; *P*=0.04). The incidence of MACE in the PCI group did not decrease significantly compared to the CABG group (OR: 0.93, 95% CI: 0.47-1.84, *P*=0.83).

Myocardial Infarction
---------------------

Six of eight studies reported 105 MIs during follow-up. Comparing with MT, a reduction in MI was observed among PCI-treated patients (OR: 0.40, 95% CI: 0.26-0.62; *P*\<0.001), but not among CABG-treated patients (OR: 0.23, 95% CI: 0.03-1.54; *P*=0.13). However, we did not find a difference in MI between PCI and CABG groups (OR: 1.88, 95% CI: 0.75-4.71, *P*=0.18).

Cardiac Death
-------------

Five of eight studies reported 324 cardiac deaths during follow-up. Comparing with MT, PCI presented lower cardiac death (OR: 0.40; 95% CI: 0.31-0.52; *P*\<0.001). We did not find CABG associated with fewer incidence of cardiac death compared to MT (OR: 0.83, 95% CI: 0.51-1.35). Comparing with CABG, PCI did not show advantage in reducing cardiac death risk (OR: 0.45, 95% CI: 0.17-1.22, *P*=0.12).

Publication Bias Analysis
-------------------------

In the present study, we utilized funnel plots to evaluate the publication bias of all included studies. No publication bias was identified in this meta-analysis ([Figure 3](#f3){ref-type="fig"}).

Fig. 3Funnel plot of the association between management strategy and prognosis of coronary chronic total occlusion patients.

Sensitivity Analysis
--------------------

Sensitivity analysis was performed to examine the influence of each study on the pooled ORs by deleting each study one at a time. The pooled ORs showed no significant change ([Figure 4](#f4){ref-type="fig"}), suggesting the results are stable.

Fig. 4Results of sensitivity analysis. CABG=coronary artery bypass grafting; CI=confidence interval; MT=medical treatment; PCI=percutaneous coronary intervention.

DISCUSSION
==========

The results of this systematic review and meta-analysis of comparison of clinical outcomes among PCI, CABG, and MT in patients with coronary CTO show that PCI presented a 54% reduction in all-cause mortality, a 45% reduction in MACE, a 60% reduction in MI, and a 60% reduction in cardiac death, compared with MT. Similarly, CABG presented a 50% reduction in all-cause mortality and a 50% reduction in MACE, compared with MT. However, compared with CABG, PCI does not have the advantage of decreasing mortality, MI, cardiac death, and MACE in coronary CTO patients. This is the first meta-analysis to compare the clinical outcomes of revascularization *vs*. MT alone in the treatment of coronary CTO patients.

The association between revascularization and low risk for subsequent cardiovascular events may be causal. Revascularization may improve the clinical outcomes of CTO patients by reducing or eliminating myocardial ischemia, which has been linked to worse prognosis^\[[@r17]\]^. At present, our meta-analysis suggested that both PCI and CABG improve the clinical outcomes in comparison with MT. The rates of all-cause mortality, cardiac death, MI, and MACE observed in the MT group were relatively higher than those of the revascularization group (PCI or CABG). Therefore, the findings of the present study have a practical application for cardiologists and surgeons alike. Given the strong clinical benefit in patients with CTO, PCI/CABG may be the optimal management strategies. The incidence of CTOs in the coronary artery disease (CAD) population is from 13% to 24%^\[[@r1],[@r18]-[@r19]\]^, however, CTO-PCI was performed in only 5-14% of patients with CTO^\[[@r20],[@r21]\]^. There are several factors which impact the management of CTO patients. Jolicoeur et al.^\[[@r22]\]^ reported that the number of diseased vessels, absence of previous MI, and angina are the strongest predictors of undergoing CTO-PCI. However, following the development of modern techniques and devices for CTO recanalization, the indications are currently increasing. Our meta-analysis\' results suggest that PCI/CABG are the best treatment strategies for CTO patients. Furthermore, although our results did not show significant differences in prognosis between CABG and PCI, comparing with MT, PCI presented decreased risks of mortality, cardiac death, MI, and MACE, but CABG only presented decreased risks of mortality and MACE, but not of MI and cardiac death. This fact suggested that PCI rather than CABG might be the best choice for CTO management strategy. However, the revascularization strategy may be influenced by the SYNTAX score and chronic total occlusion SYNTAX score (CTO-SS). In our meta-analysis we did not consider the effect of SYNTAX score and CTO-SS on management strategy selection because they were not provided in the original literatures. Therefore, our results should be further confirmed by future large-scale clinical studies.

Study Limitations
-----------------

First, in our meta-analysis, many of the included studies had different entry criteria, study populations, clinical outcomes, and follow-up time. This is a source of increased heterogeneity that may limit the generalizability of our conclusions to the broader coronary CTO population. Second, all the included studies are not randomized trials, therefore, the selection of the treatment group was likely influenced by patients\' characteristics and patients\' and doctors\' preferences. Third, regarding the participants in each study, including both single CTO and multivessel CTO, we did not perform a subgroup analysis according to the number of CTOs, due to the absence of original data. Fourth, the comparison of PCI *vs*. CABG should be interpreted with caution, because the SYNTAX score and CTO-SS were not described in some included studies. Finally, optimization or standardization of MT will affect the clinical outcomes, which should not be underestimated. In our meta-analysis, a stratified analysis of MT was not performed due to the absence of related data in the included studies.

CONCLUSION
==========

In this first systematic review and meta-analysis of PCI, CABG, and MT in patients with coronary CTO, PCI/CABG were associated with better prognosis than MT. However, PCI is not better than CABG in decreasing mortality, MI, cardiac death, and MACE in coronary CTO patients.
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